Understanding Why Alzheimer’s Disease-Related Brain Damage Doesn’t Immediately Trigger Symptoms

Examining Resilience to Alzheimer’s Disease: Why Some Individuals Remain Symptom-Free

Associated Press/Alamy

Recent studies reveal that some individuals exhibit brain changes tied to Alzheimer’s disease yet show no symptoms like memory loss. Though the reasons remain unclear, innovative research is uncovering protective factors that may prevent cognitive decline.

Alzheimer’s disease is marked by amyloid plaques and tau tangles accumulating in the brain, widely believed to contribute to cognitive decline. However, some individuals, known for their resilience, defy this notion. In 2022, Henne Holstege and her team at the University Medical Center in Amsterdam discovered that certain centenarians retain good cognitive function despite these pathological changes.

Expanding on this research, the team conducted a new study involving 190 deceased individuals. Among them, 88 had Alzheimer’s diagnoses, while 53 showed no signs of the disease at death. Their ages ranged from 50 to 99, and 49 were centenarians with no dementia, though 18 exhibited cognitive impairment previously.

The focus was on the middle temporal gyrus—an early site of amyloid plaques and tau tangles in Alzheimer’s. Interestingly, centenarians with elevated amyloid levels had tau levels akin to those without Alzheimer’s, suggesting that limiting tau accumulation is critical for resilience, according to Holstege.

While amyloid plaques are linked to cognitive decline, Holstege posits that tau accumulation may activate a cascade of symptoms. Notably, amyloid plaques alone may not cause significant tau tangling. “Without amyloid, tau can’t spread,” she explains.

Further analysis of approximately 3,500 brain proteins revealed only five were significantly associated with high amyloid plaques, while nearly 670 correlated with tau tangles. Many of these proteins are involved in crucial metabolic processes like cell growth and waste clearance. Holstege emphasizes, “With amyloid, everything changes; with tau, it’s a different story.”

In the cohort of 18 centenarians with high amyloid levels, 13 showed significant tau spread throughout the middle temporal gyrus, a pattern similar to Alzheimer’s, but the overall tau presence remained low.

This distinction is vital, as diagnosis hinges on tau spread, indicating that accumulation, not just proliferation, triggers cognitive decline. “We must understand that proliferation doesn’t mean abundance,” Holstege clarifies.

In a second study, Katherine Prater and her team at the University of Washington examined 33 deceased individuals—10 diagnosed with Alzheimer’s, 10 showing no signs, and 13 deemed resilient. Most subjects were over 80 and underwent cognitive assessments within a year before death.

In line with previous findings, the research indicated that tau was present but not accumulated in resilient brains. Though the mechanisms remain elusive, Prater theorizes that microglia—immune cells regulating brain inflammation—might play a crucial role in maintaining cognitive function in resilience.

Previous research has shown that microglia often become dysfunctional in Alzheimer’s disease, contributing to degenerative processes. While the researchers could not analyze microglia extensively, Holstege noted their significance.

The team also conducted genetic studies on microglia from the dorsolateral prefrontal cortex, essential for managing complex tasks. They discovered that resilient individuals’ microglia exhibited heightened activity in messenger RNA transport genes compared to those with Alzheimer’s. This suggests effective gene transport, vital for protein synthesis, is preserved in resilient brains.

“Disruptions in this process can severely impact cell function,” Dr. Prater remarked at the Neuroscience Society meeting in San Diego. However, its direct relationship to Alzheimer’s resilience remains to be elucidated.

Moreover, resilient microglia demonstrated reduced activity in metabolic energy genes compared to those in Alzheimer’s patients, mirroring patterns in healthy individuals. This suggests heightened energy expenditure in Alzheimer’s due to inflammatory states that disrupt neuronal connections and lead to cell death.

“Both studies indicate that the human brain possesses mechanisms to mitigate tau burdens,” Prater concludes. Insights gained from this research could pave the way for new interventions to delay or even prevent Alzheimer’s disease. “While we aren’t close to a cure, the biology offers hope,” she stated.

Topics:

  • Brain/
  • Alzheimer’s Disease

Source: www.newscientist.com

Testosterone Boosts Sex Drive During Menopause – Could It Alleviate Other Symptoms Too?

Therapy that balances testosterone and estrogen reduces menopausal symptoms

Alamy Stock Photo

The menopause can bring a host of challenging symptoms such as mood fluctuations, difficulties in concentration, and a decline in sexual drive. Hormone replacement therapy is commonly sought to alleviate these issues, primarily focusing on restoring estrogen and progesterone levels, which drop significantly during midlife. Recent studies indicate that testosterone may also play a crucial role in managing various menopausal symptoms beyond just libido, including mood improvement and muscle retention.

While typically categorized as a male hormone, testosterone is also present in women, albeit at lower levels—approximately ten times less than in men. Dr. Sarah Glynn, a contributor to menopause treatment guidelines at the British Society of Sexual Medicine, notes that limited understanding of testosterone’s effects has hindered research in this area, but recent findings are changing that narrative. Increasing evidence highlights the hormone’s crucial role in women’s sexual health and its potential benefits for cognitive, muscular, skeletal, and urinary function.

Approximately half of a woman’s testosterone is produced by the ovaries, with the remainder being synthesized by the adrenal glands. Testosterone levels generally peak in the 20s and begin to decline gradually after age 30, with production halving by middle age. Dr. Sharon Parrish from Cornell University mentions that although this decline often coincides with menopause, it may not be a direct result of it.

We know little about the health implications of this decline, but it is evident that it can reduce sexual interest. “[Testosterone] plays a critical role in sexual function,” states Dr. Joan Pinkerton from UVA Health in Virginia, influencing factors such as sexual arousal, desire, and lubrication. Consequently, it makes sense that nearly half of menopausal and postmenopausal women experience issues with sexual desire, with a leading cause being hypoactive sexual desire disorder (HSDD)—a distressing lack of sexual fantasies or desire lasting at least six months. In a survey of 1,800 postmenopausal women in Europe, over one-third reported reduced desire and more than half indicated decreased interest in sex.

The notion that low testosterone contributes to diminished sex drive was established in the 1940s. Numerous studies have consistently shown that testosterone replacement therapy can enhance sexual function in menopausal women. For instance, a 2005 report involving 533 women who underwent hysterectomies noted that those receiving testosterone patches along with estrogen reported more satisfying sexual experiences than those on estrogen alone. A similar study in 2010 corroborated these findings with 272 menopausal participants.

In 2019, a meta-analysis encompassing over 80 studies involving 8,480 women demonstrated that testosterone treatment for postmenopausal women significantly heightened sexual desire and increased frequency of sexual satisfaction, arousal, orgasm, and overall self-esteem. This study garnered support from approximately 12 medical organizations, including the International Menopause Society, the Royal College of Obstetricians and Gynecologists, and the North American Menopause Society, which endorsed the use of testosterone for HSDD.

Testosterone enhances sex drive by interacting with brain receptors that activate the neural pathways governing desire, explains Parrish. Thus far, only four countries—Australia, New Zealand, South Africa, and the UK—have approved women-specific testosterone products. The U.S. Food and Drug Administration (FDA) has yet to approve these, citing insufficient data on potential long-term side effects. Nevertheless, Professor Parrish argues this caution is unwarranted, stating that some studies have tracked participants for years without revealing increased risks of cardiovascular, breast, or uterine issues.

“Most healthcare providers focused on menopausal women seek an FDA-approved testosterone therapy that is both safe and effective. We genuinely believe there’s an urgent need for such treatments, particularly concerning sexual health,” Pinkerton comments.

Finding the Right Balance

Women report feeling more like themselves after menopausal hormone treatment

Cavan Image/Alamy

Some medical professionals believe that testosterone therapy can extend benefits beyond just sexual health. A 2023 analysis covering seven studies found that testosterone may contribute to increased muscle mass, reduction in body fat, and improvements in insulin sensitivity and cholesterol levels. In 2024, Glynne and her team assessed hormone therapy in 510 women experiencing perimenopause and menopause who were also on estrogen. After four months, around 50% reported fewer anxiety episodes and less crying, while approximately 40% noted improvements in mood, focus, and fatigue. More than a third experienced enhanced memory and reduced irritability. “Common feedback is that women feel more like themselves—stronger and more empowered,” states Glynn.

Yet, skepticism remains. Pinkerton cautions that many of these studies lacked control groups, relying heavily on self-reports, which raises questions about whether improvements were genuinely due to testosterone or might be attributed to a placebo effect. “There’s some evidence concerning cognition, mood, muscle strength, cardiovascular health, and bone health, but the lack of substantial randomized controlled trial efficacy and safety data doesn’t justify recommendations for these issues,” Parrish remarks.

Most clinical trials combine testosterone therapy with estrogen, though some studies indicate that testosterone alone can effectively enhance sexual function. However, due to frequent side effects such as acne and excessive hair growth, it is generally not advised. Glynne prefers to prescribe estrogen initially, adding testosterone only if symptoms remain unresolved.

Experts agree that comprehensive clinical trials focusing on testosterone’s impacts beyond sexual health are urgently needed. Questions concerning optimal timing, dosage, and duration also persist, as Pinkerton highlights.

What stands out is that many current menopause treatments fall short for numerous individuals, particularly those with a history of hormone-sensitive breast cancer who are hesitant to undergo estrogen therapy due to concerns regarding potential tumor growth or recurrence. “This represents a significant gap in knowledge, and we need more data,” Glynn concludes.

Topics:

Source: www.newscientist.com

Low-Dose Lithium Alleviates Alzheimer’s Symptoms in Mice

Illustration of neurons impacted by Alzheimer's Disease

Illustration of neurons affected by Alzheimer’s disease

Science Photo Library / Alamy Stock Photo

Research indicates that administering lithium to mice with low brain levels reverses cognitive decline associated with Alzheimer’s disease. These findings imply that lithium deficiency could contribute to Alzheimer’s, and low-dose lithium treatments may have therapeutic potential.

Several studies have highlighted a relationship between lithium and Alzheimer’s. A 2022 study found that individuals prescribed lithium faced nearly half the risk of developing Alzheimer’s. Another paper published recently linked lithium levels in drinking water with a reduced risk of dementia.

However, as Bruce Yankner from Harvard University points out, hidden variables may influence these results. He suggests that other elements in drinking water, like magnesium, might also contribute to a lower dementia risk.

Yankner and his team assessed metal levels in the brains of 285 deceased individuals, 94 of whom had Alzheimer’s, and 58 exhibited mild cognitive impairment. The remaining participants showed no cognitive decline prior to death.

They discovered that lithium concentrations in the prefrontal cortex (a vital area for memory and decision-making) were about 36% lower in those without cognitive decline, and 23% lower in individuals with mild cognitive impairment. “I believe environmental factors, including diet and genetics, play a significant role,” states Yankner.

There’s another concerning aspect. In Alzheimer’s patients, amyloid plaques exhibited nearly three times more lithium than areas without plaques. “Lithium is sequestered by these plaques,” explains Yankner. “Initially, there’s a lithium intake disorder, and as the disease advances, lithium levels decline further due to its binding to amyloid.”

To further investigate cognitive effects, the research team genetically modified 22 mice to mimic Alzheimer’s symptoms and reduced their lithium consumption by 92%. After around eight months, these mice performed significantly worse on various memory assessments compared to 16 mice on normal diets. For instance, even after six days of training, lithium-deficient mice took approximately 10 seconds longer to locate a hidden platform in a water maze. Their brains also had about 2.5 times more amyloid plaques.

Genetic evaluations of brain cells from the lithium-deficient mice indicated heightened activity of genes linked to neurodegeneration and Alzheimer’s. These mice experienced increased encephalopathy, and their immune cells failed to eliminate amyloid plaques, mirroring changes seen in Alzheimer’s patients.

The researchers then evaluated various lithium compounds for their ability to bind with amyloid and found that orotium— a compound created through the combination of lithium and orotic acid— had the least propensity to be trapped in plaques. A nine-month treatment regimen with orotium significantly diminished amyloid plaques in Alzheimer’s-like mice and improved memory performance compared to regular mice.

These findings point toward the potential of lithium orotium as a treatment for Alzheimer’s. High doses of various lithium salts are already being employed to manage conditions such as bipolar disorder. “A significant challenge with lithium treatment in the elderly is the risk of kidney and thyroid toxicity due to high dosages,” notes Yankner. However, he mentions that the quantities used in this study were about 1,000 times lower than those typically administered, which may account for the absence of kidney or thyroid issues observed in the mice.

Nonetheless, clinical trials are crucial to gauge how low doses of orotium lithium might impact humans, says Rudolf Tansy at Massachusetts General Hospital. “The challenge lies in determining who truly requires lithium,” he adds. “Excessive lithium intake can result in severe side effects.”

Topics:

Source: www.newscientist.com

New ‘Molecular Shield’ Offers Relief from Hay Fever Symptoms in the Nose

Sneezing and coughing are prevalent symptoms of hay fever

Mohammad Hosein Safaei/Unsplash

Individuals suffering from hay fever may find relief with a novel “molecular shield” designed to stop pollen from penetrating the nasal lining, likely with fewer side effects than traditional treatments.

Hay fever is an allergic response triggered by pollen interacting with IgE antibodies found in the nose, mouth, and eyes, leading to inflammation and symptoms like sneezing and itching. Common treatments, such as antihistamines and steroids, help reduce inflammation but often come with side effects, including drowsiness.

Seeking alternatives, Kaissar Tabynov from Kazakh National University of Agricultural Research and his team first collected blood samples from mice. They then isolated antibodies that did not participate in the allergic response but could bind to major mugwort pollen allergens, the primary trigger for hay fever. This binding action inhibited allergens from connecting with IgE antibodies in laboratory tests. “It acts as a molecular shield,” Tabynov explains.

To evaluate the shield’s effectiveness, the researchers induced mugwort pollen allergies in 10 mice by injecting them with allergens and chemicals to stimulate an immune response.

After a week, they administered small amounts of liquid containing the pollen-blocking antibodies into the noses of half the mice, gradually increasing the dosage over five days. The other group received saline solutions. An hour following each droplet, the mice were exposed to mugwort pollen at concentrations similar to those encountered during peak pollen seasons, according to Tabynov.

Following the final injection, the mice receiving the antibody treatment showed an average of 12 nose rubs over five minutes, in stark contrast to 92 in the saline group.

The researchers aimed to diminish inflammation and confirmed their success by imaging the nasal tissues collected from the mice at the study’s conclusion. This imaging revealed that the treatment not only had localized effects but also systemic ones. “Our research is the first to show that allergen-specific monoclonal antibodies can be administered intranasally to achieve both local and systemic protection against plant pollen allergies,” states Tabynov.

While the researchers did not assess potential side effects, they do not anticipate the adverse reactions associated with oral hay fever treatments, since the antibodies act at the site of allergen entry.

“This study represents a significant breakthrough and underscores the promise of intranasal therapies for allergic rhinitis. [hay fever] It lays the groundwork for early clinical trials exploring this method in humans,” remarks Sayantani Sindher from Stanford University in California.

Nonetheless, translating success in mice to human applications may prove challenging, and the antibodies will need to be modified to ensure they do not provoke an unexpected immune response in humans, Tabynov notes. If all goes well, the team hopes to advance this method to a nasal spray for human use within the next two to three years, he adds.

Such sprays could also address additional pollen types responsible for hay fever. “We envision a future where tailored antibody sprays can be made for individuals with sensitivities to different pollen varieties,” muses Tabynov.

topic:

Source: www.newscientist.com

Antidepressant Withdrawal Symptoms Might Be Less Prevalent Than Believed

SEI 258421425

Withdrawal symptoms from antidepressants can include nausea and headaches.

Savushkin/Getty Images

While antidepressant withdrawal symptoms may not be as frequent as presumed with short-term usage, inquiries persist regarding the impact on individuals ceasing the medication after prolonged periods.

Individuals utilizing antidepressants for conditions like depression, anxiety, or phobias might experience withdrawal effects lasting several weeks, such as nausea, headaches, anxiety, and more. Though physicians may caution patients about this potentiality, the frequency of occurrence remains uncertain.

To delve deeper, Sameyer Jauhar from Imperial College London and his research team examined 49 randomized controlled trials concerning antidepressant consumption. They initially focused on a subgroup of studies tracking withdrawal symptoms experienced a week after discontinuation of antidepressants, in comparison to those on placebo or ongoing antidepressant treatment. The findings revealed that individuals who ceased the medication reported one additional symptom compared to those in the other groups.

In further analysis, the researchers scrutinized another subset of studies that observed the types of withdrawal symptoms faced by participants after stopping antidepressant or placebo tablets. Dizziness emerged as the most prevalent symptom, followed by nausea, tension or irritability.

Specifically, 7.5% of the antidepressant users experienced dizziness, compared to just 1.8% in the placebo cohort. Nausea, tension or irritability, and dizziness were reported by fewer than 5% of users in the antidepressant group, with under 2% in the placebo cohort.

These statistics are significantly lower than past projections for withdrawal symptoms. A review from 2019 reported that over half of individuals had faced symptoms, although this data stemmed from online surveys that might attract those experiencing more severe reactions. Michael Browning from Oxford University commented.

Another study published last year indicated that 31% of participants reported withdrawal symptoms, in contrast to 17% from the placebo group. However, specifics regarding the symptoms experienced were not detailed, mentioned Jauhar.

Susanna Murphy at Oxford University believes the recent reviews tackle these issues effectively. “This is essential for the field as it compiles and synthesizes data from many robust studies with a broader participant base compared to previous ones,” she stated.

Conversely, John Reed from East London University noted that most trials in the review focused on individuals who took antidepressants for only 8 to 12 weeks and pointed out that many patients remain on these medications for years. “There’s a notable correlation between the duration of antidepressant use and the likelihood of withdrawal symptoms, thus short-term studies may not adequately reflect actual outcomes,” he explained.

Therefore, they emphasize the necessity for further research to understand the implications of long-term use. Mark Horowitz from University College London illustrated this by saying, “It’s akin to crashing a car into a wall at 5 kilometers per hour and declaring it safe while ignoring that real-world driving speeds can reach 60 kilometers per hour.”

Topics:

Source: www.newscientist.com

Life-Threatening Symptoms of Benzodiazepine Withdrawal

Tasha Hedges used Xanax for two decades to manage her anxiety and panic attacks, following her psychiatrist’s recommendations. However, in 2022, her doctor passed away unexpectedly.

Although the general practitioner continued the prescription, he retired shortly thereafter. The next physician moved to Canada, leaving Hedges to eventually find another psychiatrist.

“The first thing he did was yell at me for being on Xanax for too long,” she recounted from W.Va.

Typically, discontinuing the medication requires a gradual reduction of dosage over several months or years, referred to as tapering. However, Hedges stopped abruptly, facing severe withdrawal symptoms such as hot flashes, cold sweats, restlessness, shaking, and teeth grinding.

“It was a nightmare,” she described. Two years after ceasing the medication, she still grapples with repercussions. “My brain wasn’t the same.”

Online support groups and platforms like Benzobuddies indicate that individuals like Hedges are physically dependent on benzodiazepines. Many encounter serious and potentially dangerous withdrawal symptoms when their medication is abruptly ceased or tapered too quickly, leading to extended periods without treatment. Some healthcare providers hesitate to prescribe these medications due to associated risks and stigma.

“They’re often seen as highly addictive,” noted Ronald M. Winchell, a clinical psychiatry professor at Columbia University, who posed several questions to consider: “Would I initiate this treatment? Is it appropriate? Is it safe? Could my patients misuse it? What do my peers think?”

Prescriptions for benzodiazepines such as Xanax, Ativan, and Klonopin have declined since 2016 due to provider concerns. Nonetheless, these medications remain quick and effective solutions, often being among the most prescribed in the country for anxiety and sleep disorders. In 2019, around 92 million benzodiazepine prescriptions were issued in the U.S., according to the Food and Drug Administration.

Current guidelines advise prescribers to use the lowest effective dose for the shortest duration, typically less than four weeks. However, many patients remain on these medications for longer periods. An FDA review in 2018 indicated that approximately half of patients had used the drugs for over two months. Dr. Edward K. Silverman, a professor emeritus of psychiatry at Tufts University School of Medicine, highlighted that some patients stay on these medications without regular consultations.

Patients can develop physical dependence within weeks of stable benzodiazepine use. Stopping the medication, even after a brief period, necessitates a carefully managed process. Unfortunately, many healthcare providers lack adequate training in tapering prescriptions. To clarify the process, an expert from the American Society of Addiction Medicine released new guidelines in March for dosage reduction developed with FDA funding.

“It’s absolutely reckless to force people into rapid tapering,” Dr. Silverman stated.

Jodie Jerlow, 60, began using Klonopin for insomnia 25 years ago while in Dallas. After her psychiatrist retired for health reasons, she found another doctor who recommended two additional benzodiazepines, Xanax and Ativan, while working towards withdrawing from Klonopin.

After about six months on all three medications, Jerlow grew frustrated and decided to take matters into her own hands. She successfully tapered off Klonopin and Xanax.

She is still working to discontinue Ativan with assistance from her general practitioner and a coach at the nonprofit Benzodiazepine Information Coalition.

Initially, Jerlow noted she tapered too quickly, experiencing headaches, nausea, and agoraphobia. However, one of the most distressing withdrawal symptoms was suicidal ideation.

“It felt like background noise. ‘It’s going to be easy,’” she recalled.

These were feelings she had never encountered before reducing her medication.

In 2023, advocates for those harmed by benzodiazepines reported various long-term symptoms that may arise during use, tapering, or discontinuation, including benzodiazepine-induced neurological dysfunction or binding.

While not everyone experiences binding, experts agree that with a well-planned tapering strategy, side effects can be lessened.

Dr. Carl Zalzman, a psychiatry professor at Harvard Medical School and former president of the American Psychiatry Association’s Benzodiazepine Task Force, commented on the issue.

Despite their existence since the 1960s, many healthcare providers are still at a loss regarding how to help patients discontinue these medications effectively. There is no one-size-fits-all tapering strategy. Some patients experience withdrawal symptoms, and others require continued access to medications while tapering slow.

Dr. Silverman recalled a patient who had to meticulously slice pills with a razor blade to gradually decrease dosage and mitigate severe side effects.

The new guidelines from ASAM, which address the limited studies available on effective tapering, mainly rely on clinical experience. They advise clinicians to review the risks and benefits of benzodiazepine prescriptions at least every three months, recommending a dosage reduction of 5-10% every 2-4 weeks. The guidelines stress that long-term users may need to taper for over a year and should be monitored post-discontinuation.

“Most of us were never informed of the potential for dependency and long-term complications,” said De Foster, an advocate for those suffering from benzodiazepine complications, who contributed to the new guidelines. He emphasized, “A slow taper can be challenging, but a sudden withdrawal is perilous.”

ASAM’s guidance came too late for Ratasha Marberry, 49, a New York resident who became physically dependent on Klonopin. In 2022, she entered an addiction detox center, desperate to stop the medication she had been prescribed for insomnia. The facility’s provider took her off the medication in just five days.

She shared that it felt like collapsing as she faced nights filled with turmoil akin to “a lion in the room that you can’t see but are fighting against.” She later visited another facility in Florida where she was prescribed antidepressants. Within weeks, she began to feel a significant improvement.

Now she states, “I’m sleeping like a strange baby.”

She reflects, “Should I have been prescribed this drug for an extended period rather than a benzodiazepine?”

“When I think back to my experiences, I cry,” she confessed. “It wasn’t physical pain, but rather emotional suffering. I’m thankful to be alive.”

If you are in crisis or contemplating suicide, reach out to 988 for the National Suicide Prevention Lifeline; visit Speaking of Suicide for additional resources.

Source: www.nytimes.com

Migraine Medications That Alleviate Headaches and Dizziness Symptoms

The debilitating nature of migraines can significantly hinder a person’s daily routine

Alfred Pasieka/Science Photo Library

A medication called Ubrogepant, which is currently prescribed for migraine treatment, has been found to alleviate non-headache symptoms that often precede the onset of migraines. This makes it the first medication known to address these initial signs.

Before migraine headaches decrease in intensity, many individuals experience warning signs such as light sensitivity, sounds, dizziness, and neck stiffness, all of which can significantly disrupt daily activities.

Developers of migraine medications have predominantly concentrated on treating the headaches themselves, with no effective solutions available for alleviating these preliminary symptoms.

However, Ubrogepant demonstrated promising results when administered during the early stages of migraine symptoms, according to Peter Goadsby from King’s College London and his team, who are eager to further explore this potential.

Their study involved 438 participants, aged 18 to 75, all with a history of migraines. Half received a 100 mg dose of the medication upon experiencing suggestive symptoms of an impending migraine. The other half took a placebo during a subsequent episode of prodromal symptoms.

Following the administration of Ubrogepant, participants reported an enhanced ability to focus after 1 hour, decreased sensitivity to light after 2 hours, and reduced fatigue and neck discomfort after 3 hours, compared to their experiences while taking the placebo. They also noted less sensitivity to dizziness and sound when using Ubrogepant.

“Taking Ubrogepant allowed individuals to mitigate these non-pain symptoms even before the headache began,” Goadsby remarked.

This study did not delve into the impact of the medication on aura, another early feature of migraines that includes sensory disturbances like flashing lights or blind spots.

“The potential for intervention in the migraine progression is clinically significant given the often debilitating early symptoms,” remarked Parisa Gazerani from Oslo Metropolitan University, Norway. However, she emphasizes the need for further studies to ensure broad applicability.

“This research indicates that migraine treatments could lessen these preliminary symptoms and may prevent the progression to the main headache phase,” stated Rob Music, head of the Migraine Trust in the UK. “We are eager to see more investigations in this area to lessen the burden of migraines on daily living.”

topic:

Source: www.newscientist.com

Migraine Medications Are Ineffective in Alleviating Dizziness Symptoms

Here’s a rewritten version of your content while keeping the HTML tags intact:

Rizatriptan is frequently recommended for various migraine types

Aleksandr Zubkov/Getty Images

The standard medications prescribed for migraines provide limited relief for the vestibular symptoms, which include dizziness and typical migraine manifestations like headaches and light sensitivity. This is true even for rizatriptan, which is sometimes recommended for such types of migraines.

Research on vestibular migraine treatment has been inconsistent, yielding mixed results across different medications, according to Jeffrey Staab from the Mayo Clinic in Rochester, Minnesota. Some newer medications, like galcanezumab, may reduce the frequency of attacks, but no randomized trials have previously evaluated the effectiveness of migraine medications in alleviating vestibular symptoms during episodes.

To fill this research gap, Staab and his team investigated vestibular migraines. Participants were instructed to take 10 milligrams of rizatriptan or a placebo at the onset of vestibular symptoms, such as balance problems and spinning sensations. Their symptoms were subsequently evaluated on a scale of 0 to 3 at several intervals until the episodes resolved.

One hour after administration—at which point rizatriptan reaches peak concentrations in the bloodstream—it was not more effective than the placebo in relieving symptoms which are often considered to act quickly. Both groups were allowed to use back-up medications after waiting the necessary hour.

After 24 hours, rizatriptan showed a slight improvement in sensitivity to movement, light, and sound, but not in dizziness. Participants also reported marginally higher scores concerning physical well-being—such as energy levels and the ability to carry out daily activities—when compared to those taking the placebo. However, no differences were noted in mental well-being or the acceptance of side effects.

Rizatriptan falls under the triptans class of drugs, typically effective against migraines, but may not alleviate vestibular symptoms, as noted by Staab.

The study’s findings indicate that the brain pathways linked to vestibular migraines (the vestibular system, which is considered “primitive” from an evolutionary standpoint) may lack sensitivity to triptans for reasons that are yet to be explored. According to Peter Goadsby from King’s College London, vestibular migraines should not be treated as distinct conditions from other migraine types; rather, their symptoms represent a “slight variation” of migraine pathology that necessitates targeted treatment approaches.

“I think it’s important to communicate with fellow clinicians about these symptoms,” Goadsby states. “For instance, if you are treating someone with a vestibular migraine using a triptan, be prepared for it to potentially be ineffective. It’s crucial to recognize that this doesn’t imply the patient is difficult or unreasonable.”

Topics:

This retains the original HTML structure while rephrasing the content for clarity and flow.

Source: www.newscientist.com

Counterfeit drugs alleviate PMS symptoms.

Placebo pills can have real effects through the power of suggestions

72 images / Aramie

Women with premenstrual syndrome appear to benefit from the placebo effect, even if they know they are taking Siamese medication. This suggests that we can provide cheap and simple treatments.

Premenstrual syndrome (PMS) with symptoms such as anxiety, mood swings, and abdominal cramps generally affects people with periods of time. Previous research has shown this Placebo pills can reduce symptoms It was unclear whether these benefits remained when people intentionally taking fake medications in women who think they might be taking real medications.

Antje Frey Nascimento The University of Basel in Switzerland and her colleagues recruited 150 women in Switzerland, ages 18-45. In a study that acquired symptoms of 27 PMS on a scale of 0 to 5, participants rated at least one symptom A 4 or 5 at the start of the study. Participants also reported that at least one symptom interfered with society, work, or school life and scored this confusion.

The researchers then randomly assigned a third of participants, taking two placebo pills daily in two menstrual cycles, and informing these people that they are taking Placbos. Another third of participants also took placebo pills, but received additional explanations on how placebo can alleviate symptoms through the power of suggestions and belief.

The remaining third of participants were not given a placebo, but all groups were able to take regular medication. All participants completed a daily survey of PMS symptoms and how much these lives interfered.

By analyzing survey data from participants’ last menstrual cycle, the team found that on average, those who took placebo without explanation, the intensity of PMS symptoms decreased by 50%. These symptoms were half that destroyed their lives.

Those who took the placebo in their explanation reported a 79% reduction in the intensity of symptoms and an 83% reduction in life disruption. “It’s a really big effect you’ll notice in your life.” Stephen Schmidt He was not involved in research at the University of Freiburg, Germany.

When people take placebo pills, they may unconsciously and consciously expect relief from the placebo effect. This appears to produce real improvements by causing the body’s natural release of painkillers, such as endorphins, Schmidt says.

“We live in a pill society where you have all the knowledge about how you get all the benefits of science in your body when you take them, so people expect to feel better,” he says. Emphasizing these potential benefits for people seems to increase their effectiveness, he says.

Despite not taking pills, the control group showed a 33% reduction in symptoms intensities, with 46% less destructive than before. “If you sign up for a study and complete these daily diaries, you can pay more notices when you feel better or when your symptoms improve, so you can see benefits without taking pills,” Schmidt says.

One limitation of this study, he adds, is the greater advantage of placebo effects, as those enrolled in the trial may be more open to alternative treatments than the wider population.

Large studies need to determine whether these placebo benefits last for a long period of time and whether they apply to older adults groups and to a wider range of people in other countries, Schmidt says. If the results endure scrutiny, he says, placebo can ultimately provide an inexpensive and easy way to treat serious health burdens.

topic:

Source: www.newscientist.com

Children and teenagers experience varying symptoms from Long Corona

The impact of the long corona pandemic appears to vary by age

Damir Cudic/Getty Images

Symptoms of long COVID appear to be very different in young children and adolescents, and a better understanding of how the symptoms manifest could aid in diagnosis.

So far, most research on long-COVID has focused on adults, in part because of a “misconception that children can't get long-COVID,” he said. Rachel Gross At New York University.

Gross and his colleagues are currently following 751 children ages 6 to 11 and 3,109 children ages 12 to 17 whose parents say they had previously been infected with the SARS-CoV-2 virus.

The researchers defined long COVID as having at least one symptom that lasted more than a month, started or worsened during the COVID-19 pandemic, and was present at the time of the study.

Among young children, these symptoms primarily included sleep problems, difficulty concentrating, and abdominal problems such as pain, nausea, vomiting, and constipation.

The symptoms were uncommon among about 150 children of the same age who had not previously been infected, and were confirmed by the absence of antibodies against the virus in their blood samples.

In contrast, symptoms in the 1,300 uninfected young people typically included pain, fatigue and loss of smell or taste.

It's unclear why symptoms differ across different age groups, but Gross said it could be due to differences in hormones or immune systems, or that teenagers may simply be better able to vocalize their symptoms than younger kids. Danilo Buoncenzo A study from the Gemelli University Hospital in Rome, Italy. For example, a teenager may complain of fatigue, but a caregiver may only notice lingering symptoms in a younger child when they vomit.

Armed with this data, the researchers developed a score that ranks how likely a young person's symptoms are to have long-Covid. Currently, diagnosis depends on doctors ruling out other illnesses and recognizing that long-Covid can take many different forms. “Doctors would prefer a score or more objective criteria. Such a tool would definitely help clinicians at least recognize that a child may have long-Covid,” Buoncenso said.

topic:

Source: www.newscientist.com

The current understanding of symptoms in the nine US cases according to scientists

summary

  • Four poultry workers in Colorado recently fell ill with avian flu, bringing the total number of cases in the United States to nine.
  • Almost all of the infections have been reported since April, giving experts a preliminary idea of what symptoms the virus causes in people.
  • Cases have been fairly mild, with some typical flu symptoms and some reports of conjunctivitis.

Four poultry workers in Colorado recently fell ill with avian flu, bringing the total number of cases in the United States to at least nine.

Though the numbers are small, researchers say the commonalities between the cases — all but one of which were reported in the past four months — are enough to get a sense of how the virus affects people.

Cases in the US have been relatively mild and limited to farm workers who have handled infected animals, suggesting that the virus in its current form does not pose a significant threat to humans.

Some patients have reported typical flu symptoms such as fever, chills, cough, sore throat, and runny nose, while a few have also developed conjunctivitis and measles.

“One thing we can say is that the current strain of the virus is not adapted to infect humans and may not be adapted to infect the lower respiratory tract,” said Matthew Binnicker, director of the Clinical Virology Laboratory at Mayo Clinic.

The cases have been attributed to the global outbreak of H5N1, a specific strain of avian influenza that swept through America’s poultry and dairy farms in 2020.

The first case in the country was reported in April 2022 in an inmate working on a farm in Colorado who was culling birds and whose only symptom was fatigue. Texas reported a second case in April, followed by two in Michigan and five in Colorado, the latest four of which were confirmed over the weekend.

The mild nature of these cases contrasts with the effect of influenza on birds and some mammals, such as seals, sea lions, foxes, skunks, and cats, which have died from the virus. There are over 99 million wild waterfowl, commercial poultry, and household chickens in the United States. Infected animals either died from the virus or were culled to prevent further infection. 160 dairy cows Since the virus was first detected in cattle in March, many cattle have become infected.

This H5N1 strain is considered highly pathogenic, which, when the term is used in the context of avian flu, means it has a high chance of killing chickens.

“It’s really scary to hear about such viruses, but the term is actually the USDA term for what happens to poultry,” said John Lednicky, professor of environmental and global health studies at the University of Florida. “Just because it’s highly pathogenic for birds doesn’t mean it’s highly pathogenic for mammals or for humans.”

Lednicky added that some H5N1 strains are deadly to humans, but others are not.

Since 1997, more than 900 total cases of H5N1 have been reported worldwide, about half of which were fatal. But the global mortality rate has fallen to about 27% over the past two years. Still, that figure largely reflects only those whose illness was severe enough to cause them to seek medical treatment.

Dr. Peter Parese, a professor of microbiology at the Icahn School of Medicine at Mount Sinai, said the figures include patients “who were hospitalized and, in retrospect, came into contact with a lot of the virus.”

Palese’s 2012 StudyBlood samples from 12,500 people with no recorded history of avian flu infection were examined and found that 1% to 2% of them may have had a previous infection with H5N1.

But experts worry the virus could one day mutate and cause more severe illness or become more capable of spreading from person to person (all transmission so far has been from animals to people).

“The concern is that as it infects more animals and then infects more humans, the virus will change,” Binnicker said.

Why is conjunctivitis associated with bird flu?

At least four of nine people with avian flu in the United States reported having conjunctivitis.

This was the case in at least one recent case in Colorado, linked to an outbreak at a commercial farm in Weld County where workers were slaughtering poultry.

The state announced earlier this month that another patient Dairy workers People who came into contact with the infected cows also developed conjunctivitis.

A dairy farm worker in Texas was infected with avian influenza and developed conjunctivitis.
New England Journal of Medicine

Texas 1 The patient had conjunctivitis and no other symptoms. The patient worked with dairy cows and developed redness and discomfort in her right eye in March. New England Journal of Medicine Case StudyThe individual reported wearing gloves while working but no eye protection.

Conjunctivitis is not the most common human symptom of avian influenza, but It has been recorded by some people Examples of infection with different strains H7N7 virus that emerged in the Netherlands in 2003.

Scientists say there could be a few factors that explain the recent spread of the condition. One is that farm workers don’t always cover their eyes when handling sick animals, which could result in dairy farmers ingesting raw milk, which can lead to infection. Carrying the virus — That’s how it seemed to them.

Perhaps it is Michigan Dairy Workers He developed mild conjunctivitis in May and was confirmed to have been infected with avian influenza.

The virus can also get into a person’s eye through respiratory droplets or aerosols (tiny droplets in the air), or by workers who touch the eye after handling infected animals or contaminated raw milk.

“The receptors on cells that the virus needs to bind to are quite abundant on cells in the eye, which may be one reason why people with avian flu have conjunctivitis,” Binnicker said.

The Centers for Disease Control and Prevention recommends treating people infected with avian flu with antiviral drugs, and some U.S. patients have been given Tamiflu, a drug also used to treat seasonal flu.

“Studies conducted to date have shown that Tamiflu is effective in treating currently circulating strains of avian flu,” Binnicker said, “and to be most effective, it usually needs to be administered within 48 hours after symptoms begin.”

Infection spreads, tests increase, number of infected people increases

Scientists say the reason why all but one of the U.S. cases have been reported since April could come down to two factors: First, the virus is spreading quickly among birds; Sporadically infect other animalsPeople who have been in contact with infected animals, such as pet cats, are more likely to become infected. Second, health officials have begun monitoring and testing people who have been in contact with infected animals if they develop symptoms.

The CDC estimates: At least 10,600 people under surveillance for bird flu At least 375 people have been tested since the outbreak began in commercial poultry in 2022.

“There’s probably a much higher amount of virus out there now than there was a year ago, but we’re also seeing more cases because we’re doing more testing,” Binnicker said.

Dr. Natasha Bagdasarian, Michigan’s chief medical officer, said local health departments are conducting tests for people with even the most minor symptoms.

“I think that’s why we’re seeing milder cases,” she said, “because of the aggressive symptom surveillance that we’re doing.”

For example, a Michigan worker who had conjunctivitis did not even see a doctor before being tested for avian flu. Other cases Farm workers who cared for the infected cows reported sore throats, coughs, and stuffy noses to local health authorities.

Baghdasarian said the fact that Michigan has tested about 60 people but has only found two cases shows it takes a lot of contact for a person to get sick, and that the workers who tested positive were not wearing full personal protective equipment and were working on tasks like milking and hydrating cows, he said.

“We’re not talking about people who have had momentary contact with these animals, who pass by a barn or a pen,” Bagdasarian said. “We’re not talking about people who only touch a cow once.”

Source: www.nbcnews.com

Excessive salt intake may trigger eczema symptoms

It is already known that excessive salt intake increases blood pressure.

Toufik Ahmed/iStockphoto/Getty Images

Researchers have found that people with the skin condition have higher levels of sodium in their urine, suggesting that excessive salt intake may be linked to eczema.

Over 200 million people Eczema affects many people around the world and is a skin condition that causes dry, cracked, itchy skin. Common causes include irritants in soaps and detergents, as well as environmental and food allergens. Previous studies have shown that: Frequent fast food consumption linked to increased risk of severe eczema For the children.

To see if salt plays a role, Katrina Abuaballah Researchers at the University of California, San Francisco (UCSF) looked at urine sample data from more than 215,800 adults who took part in the UK Biobank study, more than 10,800 of whom had eczema.

The researchers used each participant's urine sample to estimate urinary sodium excretion over a 24-hour period. About 90% of dietary sodium is excreted in the urine.This waste product therefore provides a relatively reliable way of measuring a person's salt intake.

Overall, study participants were estimated to have excreted an average of 3.01 grams of sodium in their urine over a 24-hour period. Typically around 2.5 grams per dayThis is the equivalent of 6 grams of salt, or 1 teaspoon.

The researchers found that for every gram of sodium excreted, participants were 11 percent more likely to be diagnosed with eczema, and their risk of ever developing eczema at any one time increased by 16 percent.

The team acknowledges that a single urine sample may not accurately reflect an individual's typical salt intake, but in another part of the study, the researchers looked at the daily diet of a different group of more than 13,000 U.S. adults and found further correlations between high salt intake and eczema.

In previous studies, Sodium activates immune system cells“The immune system responds to allergens and irritants in a way that triggers several inflammatory pathways,” Abuaballah said. People with eczema have an overactive immune response to allergens and irritants, which causes skin inflammation and subsequent symptoms.

Although the study suggests a link between high urinary sodium levels and eczema, team members say more research is needed to prove that the former causes the latter. Brenda Chanalso at UCSF.

“It's too early to say whether lowering sodium in the diet can reduce the severity or risk of developing eczema,” he said. Karsten Flor At King's College London.

Abuaballah said her team will soon begin enrolling participants for a National Institutes of Health-funded study that will look at the relationship between dietary sodium, sodium levels on the skin, and eczema severity.

topic:

Source: www.newscientist.com

Adopting a low FODMAP diet may be more effective than medication in reducing symptoms of irritable bowel syndrome

Eating less of some types of foods and more of others may ease irritable bowel syndrome

Aamrya/Getty Images

Two types of diets are more effective at treating irritable bowel syndrome (IBS) than drugs, a trial has found.

One diet was designed to be low in FODMAPs, a group of carbohydrates similar to sugars found in dairy products, wheat, and certain fruits and vegetables. The second, less common approach used for IBS is an adaptation of a low-carbohydrate diet that is high in fiber and low in other types of carbohydrates, such as sugar and starch.

In a randomized trial, both diets showed better symptom improvement than standard drug treatment after four weeks.

IBS can cause mysterious symptoms such as diarrhea, constipation, bloating, and abdominal pain that increase or decrease over time. The underlying cause of this condition is unknown.

The usual advice is to avoid common triggers such as caffeine, alcohol and spicy foods. Symptomatic treatments such as laxatives for constipation and drug therapy for diarrhea may be given.

If these measures don’t work, you may want to consider cutting back on foods high in FODMAPs. FODMAPs tend not to be digested until they reach the colon, which is why they are thought to cause bloating and diarrhea. This encourages the colon to retain water, and when the molecules are consumed by bacteria, gas is produced and causes bloating.

Sanna Niebacka Researchers from the University of Gothenburg in Sweden wanted to find out how a regular low-FODMAP diet compared to an alternative approach: high in fiber but low in carbohydrates. In practice, this means eating high-fat, high-protein foods such as meat and dairy products, and sources of fiber include nuts, seeds, beans, and vegetables such as cabbage.

The research team asked around 300 people with IBS to use one of three approaches depending on their symptoms: take medication or adopt one of two diets. The diet provided people with free grocery delivery, as well as detailed meal plans and recipes.

After one month, 76% of the low-FODMAP group reported a significant reduction in symptoms, compared with 71% of the low-carbohydrate diet group and 58% of the drug treatment group.

The big surprise was that a low-carbohydrate, high-fiber diet that didn’t exclude FODMAP-containing foods was about as effective as a low-FODMAP approach, Nybacka says. “We can’t answer any questions as to why. It appears that altering carbohydrate content and reducing FODMAP intake may be beneficial.”

but hazel everitt Researchers at the University of Southampton in the UK say the trial would have been more informative if it had lasted longer. “The problem with many of the IBS diets that have been proposed is that they are very difficult to stick to long-term,” she says.

Participants were followed for up to six months, but during the last five months participants who were initially offered drug treatment were also given dietary advice.

Niebacka says one potential problem with the low-carbohydrate, high-fiber diet is that this group of people had slightly elevated blood cholesterol levels. Therefore, you should seek your doctor’s advice before adopting this diet, she says.

topic:

Source: www.newscientist.com

Breakthrough App Shows Promise in Alleviating Tinnitus Symptoms

Tinnitus, a ringing in the ears, can be a debilitating problem for those who suffer from it. However, a team of researchers has discovered a potential solution to this issue.

The survey results have been published in the magazine Frontiers of audiology and otology, and an international research team can effectively reduce symptoms in just a few weeks with an app that includes sound therapy and various training courses. The study involved 30 people with tinnitus, and almost two-thirds of them experienced “clinically significant improvement” from using the app. The team will now conduct a large-scale trial in the UK in collaboration with University College London Hospital. According to Suzanne Purdy, Waipapa Taumata Rau Professor of Psychology at the University of Auckland, New Zealand, cognitive behavioral therapy is known to help people suffering from tinnitus, but it is expensive and often difficult to access.



“[The app] Cognitive behavioral therapy, mindfulness, relaxation exercises, and sound therapy can be combined to train your brain’s responses and reduce tinnitus. The sounds you perceive fade into the background and become less noticeable.”

The new app aims to tune out the sound of tinnitus, giving the mind and body tools to suppress stress hormones and responses, and reduce the brain’s tendency to focus on the sound. The Mindear app is currently available for download for Apple and Android users. Some features are free in the app, but many are locked behind a paywall after a 7-day free trial (requires a £13 monthly subscription). Another app, the sound tinnitus app, is currently undergoing clinical trials in the UK.

About 1.5 million people in Australia, 4 million in the UK and 20 million in the US suffer from severe tinnitus, according to Dr. Fabrice Bardy, an audiologist at Waipapa Taumata Rau, University of Auckland, and lead author of the study published in the journal Frontiers of audiology and otology. He adds, “One of the most common misconceptions about tinnitus is that there’s nothing you can do about it; you just have to live with it. This is simply not true. Tinnitus Support Expertise The support of professionals with knowledge and expertise can reduce the fear and anxiety associated with a healthy patient experience.”

Tinnitus itself is not a disease, but is usually a symptom of another underlying health condition, such as damage to the auditory system or tension in the head and neck. While there is no known cure for tinnitus, management strategies and techniques can help patients. For more information, please visit the provided links.

Source: www.sciencefocus.com

Early Detection of Parkinson’s Disease Possible 30 Years Before Onset of Symptoms, Scientists Find

Researchers have discovered a way to detect Parkinson’s disease up to 30 years before symptoms appear using biomarkers and PET scans. This breakthrough includes tracking neurodegeneration more sensitively than current methods and shows that rapid eye movement sleep behavior disorder (RBD) is an important early indicator of Parkinson’s disease. is identified. This discovery could lead to earlier diagnosis and treatment, potentially up to 10 years earlier than currently.

Researchers at The Florey and Austin Health in Melbourne, Australia, have demonstrated the potential to identify early indicators of Parkinson’s disease 20 to 30 years before the onset of symptoms. This breakthrough paves the way for early screening programs and intervention, potentially allowing treatment before significant damage occurs.

Researchers at the Florey Institute and Austin Health have demonstrated the possibility of identifying early indicators of Parkinson’s disease 20 to 30 years before the onset of symptoms. This breakthrough paves the way for early screening efforts and preventive treatment, long before permanent damage occurs.

Florey Professor Kevin Burnham said that although Parkinson’s disease, a debilitating neurodegenerative disease, is often thought of as a disease of the elderly, it actually begins in midlife and can last for decades. He said it may not be detected.

“Parkinson’s disease is very difficult to diagnose until symptoms become apparent, by which time up to 85 percent of the neurons in the brain that control motor coordination have been destroyed. At that point, many treatments are likely to be ineffective,” Professor Burnham said. “Our long-term goal is to find ways to detect diseases earlier and treat people before they cause harm.”

Advanced diagnostic technology

In a recently published study, neurologylead researcher Professor Burnham and colleagues explore how a known biomarker called F-AV-133 can be used in positron emission tomography (PET) scans to diagnose Parkinson’s disease and accurately track neurodegeneration. I’m explaining how it can be done.

In the Melbourne study, Austin Health’s Frawley Professor Chris Rowe and his team studied 26 patients with Parkinson’s disease, 12 controls, and 11 patients with rapid eye movement sleep behavior disorder (RBD), a strong indicator of Parkinson’s disease. I checked the name. .

Each person underwent two PET scans two years apart. Key findings include:

  • Currently available assessments of Parkinson’s disease showed no significant changes in clinical symptoms in any of the participants.
  • In contrast, PET scans showed “significant neuronal loss” in three key areas of the brains of people with the disease, making F-AV-133 more effective than what is currently available. also suggests that it is a sensitive means of monitoring neurodegeneration.

Further mathematical modeling yields the following calculation:

  • Slow nerve cell loss over a total of approximately 33 years in Parkinson’s disease
  • This loss takes about 10.5 years before the disease is detected on a PET scan.
  • Even if a PET scan detects the disease, it will take another six and a half years for motor symptoms to appear.
  • It takes about 3 years after physical symptoms appear until a clinical diagnosis is confirmed.
  • This corresponds to approximately 22.5 years of neuronal loss before clinical symptoms are sufficient for diagnosis.

Professor Burnham said the findings pave the way for the development of screening protocols to diagnose and treat Parkinson’s disease up to 10 years earlier than is currently possible. It may also help identify patients for clinical trials.

What is RBD?

  • RBD stands for Rapid Eye Movement Behavior Disorder.
  • Patients with RBD scream, thrash, and sometimes move violently during sleep, enacting vivid and disturbing dreams.
  • RBD is caused by a lack of muscle relaxation (sleep paralysis).
  • 90% of RBD patients develop Parkinson’s disease.
  • Half of all Parkinson’s patients have RBD.
  • RBD is an important warning sign for early Parkinson’s disease.
  • If you have RBD, see a sleep specialist or neurologist.

Reference: “Use of 18F-AV-133 VMAT2 PET Imaging to Monitor Progressive Nigrostriatal Degeneration in Parkinson’s Disease”, Leah C. Beauchamp, Vincent Dore, Victor L. Villemagne, SanSan Xu, David Finkelstein, Kevin J. Barnham, Christopher Rowe, 28 November 2023 neurology.
DOI: 10.1212/WNL.0000000000207748

Source: scitechdaily.com

The reasons why certain individuals do not exhibit symptoms of coronavirus infection

The peptide NQK-Q8 (light color), part of the SARS-CoV-2 spike protein that the virus uses to enter cells, bound to the groove of HLA-B*15:01 (orange color). This figure shows the crystal structure of HLA-B*15:01 in complex with the spike-derived peptide NQKLIANQF from the SARS-CoV-2 virus, published by Augusto et al., 2023 (Nature) (PDB Entry – 8ELH) It is based on.Credit: Andre Luis Lourenço

New study shows common genetic variations among people are involved in mediating SARS-CoV-2 Asymptomatic infection.

Have you ever wondered why some people don’t get sick? COVID-19 (new coronavirus infection)? Research recently published in journals Nature We show that common genetic variations among people are responsible for vectoring asymptomatic transmission of SARS-CoV-2. The results show that people with this mutation do not feel sick once infected. This exciting discovery was the result of a joint U.S.-Australian study led by Dr. Danilo Augusto, an assistant professor at the University of North Carolina at Charlotte. Dr. Jill Hollenbach, Professor, University of California, San Francisco. Stephanie Gras, a professor at La Trobe University in Australia.

The role of human leukocyte antigens (HLA)

The research focuses on a group of genes called human leukocyte antigens (HLAs). These HLA genes code for proteins that the immune system uses to identify healthy cells and distinguish them from cells infected with bacteria or viruses. The HLA system is important for the immune response, but varies widely between individuals. Because of the role of HLA in fighting infections, researchers are wondering whether there may be certain variants that make us more protected against or more susceptible to SARS-CoV-2. I thought about it. virus.

Danilo Augusto, assistant professor of biological sciences at UNC Charlotte;

Research results and methodology

Hollenback led the data collection that began early in the pandemic. First, 29,947 unvaccinated people were screened using a mobile app specifically designed to track COVID-19 symptoms, and 1,428 people tested positive for the virus. reported.everyone has their own DNA It has been pre-sequenced for HLA gene analysis. Researchers found that people with the gene mutation HLA-B*15:01 were much more likely to remain asymptomatic after infection. Remarkably, this variant is present in approximately 10% of the population. In summary, those who had HLA-B*1501 in their genome could not avoid infection, but they were spared from getting sick.

Insights into the immune response

“We hypothesized that their immune systems would respond so quickly and strongly that the virus would be cleared before they could cause symptoms. It would be because they already know what to look for. It’s like having an army where you can tell by their uniforms that they’re bad guys,” Hollenback said.

HLA molecules present parts of the virus to immune effector cells for testing. The study used cells from individuals with HLA-B*15:01 who donated blood several years before the pandemic. The results showed that these people had memory T cells against specific particles of SARS-CoV-2. People who had never had any contact with SARS-CoV-2 had already been exposed to other viruses in some way and had developed an immune memory against particles from SARS-CoV-2.

Their immunological memory would elicit a much faster response and explain why those people remain asymptomatic. Still, it remained intriguing how they were able to develop immune memory against SARS-CoV-2 without ever being exposed to this virus.

cross-reactive immune response

“It is widely known that other types of coronaviruses have been causing seasonal colds for decades. We know that these people have been exposed to seasonal coronaviruses in the past and that somehow Alternatively, we hypothesized that people specifically carrying HLA-B*15:01 could rapidly kill cells infected with SARS-CoV-2 through a cross-reactive immune response. So even if the bad guys changed their uniforms, the military would be able to identify them by a tattoo on their boots or maybe an arm. That’s how our immunological memory works to keep us healthy. ” Augusto said.

After careful analysis of the genome sequences of all coronaviruses, this study found that this SARS-CoV-2 particle, recognized by HLA-B*15:01 in unexposed individuals, was It was shown to be very similar to particles. By presenting crystal structures and affinity assays, this study demonstrated that T cells from pre-pandemic individuals can discriminate between past coronaviruses and SARS-CoV-2 virus particles with equal efficiency. This means that these individuals have created immunological memory against previous coronaviruses, but because of the high similarity of this viral particle, memory T cells also recognize SARS-CoV-2 very quickly. can be killed.

Implications and future research

The results point to a mechanism for how individuals avoid illness caused by SARS-CoV-2, and the research group plans to continue learning about responses to the virus, which could lead to treatments for COVID-19. Your understanding of the law and vaccines will deepen.

For more information about this study, see “Uncovering the secrets of the COVID-19 ‘Super Dodgers’.” Reference: “Common alleles of” HLA Asymptomatic SARS-CoV-2 Infection is Associated with .

Danilo G. Augusto, Lawton D. Murdlo, Demetra SM Chatzileontiadu, Joseph J. Sabatino Jr., and Tasneem Yousufari , Noah D. Peiser, Xochitl Butcher, Kelly Kaiser, Caroline Guthrie, Victoria by W. Murray, Vivian Pe, Sannidhi Sarvadavabatla, Fiona Beltran, Gurjot S. Gill, Carla L. Lynch, Cassandra Yun, Colin T. Maguire, Michael J. Peluso, Rebecca Ho, Timothy J. Henrik, Stephen G. Deeks, Michelle Davidson, Scott Lu, Sarah A. Goldberg, J. Daniel Kelly, Jeffrey N. Martin, Cynthia A. Vieira-Green, Stephen R. Spellman, David J. Langton, Michael J. Dewar-Aldiss, Corey Smith, Peter J. Bernard, Seulgi Lee, Gregory M. Marcus, Jeffrey M. E. Holguin, Mark J. Pletcher, Martin Myers, Stephanie Gras, Jill A. Hollenback, July 19, 2023, Nature.

Source: scitechdaily.com